Alkermes to Take Part in the 40th Annual J.P. Morgan Healthcare Conference

Rhea-AI Summary

Alkermes plc (Nasdaq: ALKS) will present a corporate overview at the 40th Annual J.P. Morgan Healthcare Conference on January 12, 2022, at 11:15 a.m. EST. CEO Richard Pops will lead the presentation, followed by a Q&A session. The event will be accessible via live webcast on the company's investor relations page and archived for 14 days. Alkermes is focused on developing innovative medicines in neuroscience and oncology, with a portfolio aimed at addiction, schizophrenia, and bipolar I disorder.

Positive

• Scheduled corporate update at a prestigious healthcare conference.
• Focus on innovative medicines in high-demand therapeutic areas.

Negative

• None.

News Market Reaction – ALKS

+3.82%

+3.82% Session move

In the trading session that priced this news, ALKS gained 3.82%, reflecting a moderate positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

DUBLIN, Jan. 5, 2022 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) announced today that its Chief Executive Officer, Richard Pops, will provide a corporate overview and update at the 40^th Annual J.P. Morgan Healthcare Conference. The presentation will take place virtually on Wednesday, Jan. 12, 2022 at 11:15 a.m. EST (4:15 p.m. GMT), followed by a question and answer session. The live webcast may be accessed under the Investors tab on www.alkermes.com and will be archived for 14 days.

About Alkermes plc
Alkermes plc is a fully-integrated, global biopharmaceutical company developing innovative medicines in the fields of neuroscience and oncology. The company has a portfolio of proprietary commercial products focused on addiction, schizophrenia and bipolar I disorder, and a pipeline of product candidates in development for neurodegenerative disorders and cancer. Headquartered in Dublin, Ireland, Alkermes plc has an R&D center in Waltham, Massachusetts; a research and manufacturing facility in Athlone, Ireland; and a manufacturing facility in Wilmington, Ohio. For more information, please visit Alkermes' website at www.alkermes.com. 

Contact:
Alex Braun
Investor Relations
+1 781 296 8493

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/alkermes-to-take-part-in-the-40th-annual-jp-morgan-healthcare-conference-301454212.html

SOURCE Alkermes plc

FAQ

When is the Alkermes presentation at the J.P. Morgan Healthcare Conference?

Alkermes will present on January 12, 2022, at 11:15 a.m. EST.

Who will lead the Alkermes presentation at the conference?

CEO Richard Pops will lead the presentation.

How can I access the Alkermes conference presentation?

The presentation will be available via live webcast on the Alkermes investor relations page.

What is Alkermes plc's focus in their development pipeline?

Alkermes is developing medicines primarily in neuroscience and oncology.

Where is Alkermes plc headquartered?

Alkermes plc is headquartered in Dublin, Ireland.